Regenerative medicine as a new product on innovation market
https://doi.org/10.38050/01300105202257
Abstract
The paper considers the state of the regenerative medicine market. The purpose of the work is to review the existing sources on the economic issues of regenerative medicine products and their introduction to the market. Due to the fact that the market for regenerative medicine is in growth stage, the number of sources is extremely limited. The review collected, analyzed and systematized data on the volume and dynamics of the market, its financing, drivers and barriers, provides a list of regulatory documents regulating the market, government support measures and opportunities for start-up entrepreneurs. The performed research characterizes the market of regenerative medicine products as a market with strong potential for growth in the next decade. The results obtained helped to identify problematic aspects of the market that require examine issues by specialized specialists. Subject to consideration of negative reviews of the federal law No. 180-FZ “On biomedical cell products” adopted on June 23, 2016, continued active state support and legal regulation, products and services of the regenerative medicine market will be able to win their niche and compete with current drugs and methods of treatment.
Keywords
Supporting agencies: The work was carried out with the support of a grant from the President of the Russian Federation for young scientists - candidates of sciences МК-2025.2021.2
About the Authors
M. S. Arbatskiy
Lomonosov Moscow State University
Russian Federation
Russian Federation
Moscow
A. S. Voronov
Lomonosov Moscow State University
Russian Federation
Russian Federation
Moscow
References
1. Association of Manufacturers of Biomedical Cell Products. Retrieved January, 10, 2022, from https://cell-industry.ru
2. Bezenkov, I. O., Batyrgazieva, D. R., & Zhukov, D. Yu. (2020). Design features of clean rooms for the production of biomedical cell products. Nauka segodnya: zadachi i puti ikh resheniya. Materiali megdunarodnoi nauchno-practicheskoi konferencii. Vologda, 27 may 2020 (p. 133–134).
3. Chaplenko, A. A., Khorolsky, M. D., Melnikova, E. V., & Merkulov, V. A. (2020).
4. Current trends in the use of cell therapy in regenerative medicine. BIOpreparations. Prevention,
5. Diagnosis, Treatment, 20(2), 82–88. https://doi.org/10.30895/2221-996X-2020-20-2-82-88 Decree of the Government of the Russian Federation dated 12/28/2012 No. 2580-r “On approval of the Strategy for the Development of Medical Science in the Russian Federation for the period up to 2025”.
6. Decree of the Government of the Russian Federation dated 31.12.2020 No. 3684-r “On approval of the Program of Fundamental scientifi c research in the Russian Federation for the long-term period (2021-2030)”.
7. Draft Decree of the Government of the Russian Federation “On approval of the Strategy for the development of the pharmaceutical industry of the Russian Federation for the period up to 2030”.
8. Dygai, A. M. (2016). Pharmacological strategy of regenerative medicine. Herald of the Russian Academy of Sciences, 86(6), 533–533.
9. Federal Law No. 180-FZ of June 23, 2016 “On Biomedical Cell Products”.
10. Forecast of scientifi c and technological development of the Russian Federation for the period up to 2030 (approved By the Government of the Russian Federation on January 3, 2014). Generium products are in development. Retrieved January, 10, 2022, from https://www. generium.ru/pipeline/
11. HealthNet NTI Infrastructure Center. (2018). Analysis of the Russian and international biomedicine market: technological and market trends. https://healthnet.academpark.com/images/bio_medicine.pdf
12. I. M. Sechenov Institute of Regenerative Medicine. Retrieved January, 10, 2022, from https://www.sechenov.ru/univers/structure/nauchno-tekhnologicheskiy-park-biomeditsiny/instituty/institut-regenerativnoy-meditsiny/
13. ISKCH is a biotech company and an industry strategic investor in various areas of modern biomedical technologies and healthcare. Retrieved January, 10, 2022, from https://hsci.ru/okompanii/hsci
14. Ivashchenko, N. P., & Engovatova, А. А. (2016). Ekonomika innovacij : Uchebnoe posobie. M.: Ekonomicheskij fakul’tet MGU imeni M. V. Lomonosova.
15. Kirillov, B. A. (2017). Russian market of biomedical technologies: advantages, complications and investing opportunities. Valyutnoye regulirovaniye. Valyutnyy kontrol, (11), 50–58.
16. Petrov, A. N., & Komarov, A. V. (2020). Estimaton of technology readiness level of tender proposal in terms of methodology TPRL. Ekonomika nauki, 6(1-2), 88–99.
17. Petrov, A. N., Sartori, A. V., & Filimonov, A. V. (2016). Comprehensive assessment of the status scientifi c and technical projects using technology project readiness level. Ekonomika nauki, (4), 244–260.
18. Resolution of the Government of the Russian Federation dated 29.03.2019 No. 377 (ed. dated 22.10.2021) “On approval of the State Program of the Russian Federation “Scientifi c and Technological Development of the Russian Federation””.
19. ROO “Society of Regenerative Medicine”. Retrieved January, 10, 2022, from https://regenerative-med.ru/
20. State Register of Medicines. Retrieved January, 10, 2022, from https://grls.rosminzdrav.ru/default.aspx
21. The official website of the Unifi ed Information System in the fi eld of procurement. Retrieved January, 10, 2022, from https://zakupki.gov.ru/epz/main/public/home.html
22. Alliance for Regenerative Medicine. Regenerative medicine annual reports. Дата обращения 10.01.2022, https://alliancerm.org/publications-presentations/#quarterly-annualreports
Supplementary files
Review
For citations:
Arbatskiy M.S., Voronov A.S. Regenerative medicine as a new product on innovation market. Moscow University Economics Bulletin. 2022;(5):125-144. (In Russ.) https://doi.org/10.38050/01300105202257
Views:
540
Email this article 